홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
NVCT
#3038
Nuvectis Pharma, Inc. Common Stock
8.8
6
-0.78%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-0.78%
월간 변동
+0.68%
6달 변화
+32.24%
년간 변동율
+27.85%
이전 종가
8.9
3
Open
8.8
6
Bid
Ask
Low
8.8
6
High
8.8
6
양
17
마켓
주식
헬스케어
NVCT
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
19.32 M
23.39 M
23.63 M
25.46 M
25.61 M
26.49 M
—
Valuation ratios
Enterprise value
104.33 M
108.05 M
201.01 M
163.36 M
118.8 M
168.41 M
651.59 M
Price to earnings ratio
-5.42
-4.87
-8.65
-6.38
-4.39
-5.72
-25.14
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
7.59
7.56
14.55
11.48
8.49
10.29
44.81
Price to book ratio
2.09
9.53
3.26
2.45
1.74
8.94
16.39
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.24
0.34
0.18
0.23
0.21
0.23
0.85
Return on equity %
0.38
0.64
0.25
0.38
0.31
0.4
1.34
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
2.74
2.09
3.28
2.66
3.07
2.38
11.4
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.14
0.14
0.21
0.16
0.2
0.18
0.75
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
1
1.08
1.5
1.25
1.56
1.45
5.76
Net current asset value per share
1
1.09
1.51
1.26
1.57
1.45
5.8
Tangible book value per share
0.64
0.57
1.05
0.79
1.06
0.84
3.74
Working capital per share
0.64
0.57
1.05
0.79
1.06
0.84
3.74
Book value per share
0.64
0.57
1.05
0.79
1.06
0.84
3.74
뉴스
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
누벡티스 파마, H.C. 웨인라이트 ’매수’ 등급 재확인
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
카플란, Nuvectis Pharma(NVCT) 주식 64,240달러 상당 매수
Nuvectis Pharma 회장, 28,600달러 상당의 주식 매입
Nuvectis Pharma 이사, NVCT 주식 7.5만 달러 매수
H.C. Wainwright, Nuvectis Pharma에 ’매수’ 등급 재확인, 목표가 $10
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Nuvectis initiates phase 1b program for cancer drug NXP900
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright